Abstract
Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Current Cancer Therapy Reviews
Title:New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Volume: 11 Issue: 4
Author(s): John P. Schwerkoske and Douglas Yee
Affiliation:
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Abstract: Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Export Options
About this article
Cite this article as:
P. Schwerkoske John and Yee Douglas, New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151215220005
DOI https://dx.doi.org/10.2174/1573394712666151215220005 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays
Current Pharmaceutical Design STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Anti-breast Cancer Agents, Quinolines, Targeting Gap Junction
Medicinal Chemistry Does More MnSOD Mean More Hydrogen Peroxide?
Anti-Cancer Agents in Medicinal Chemistry The Microarray Gene Profiling Analysis of Glioblastoma Cancer Cells Reveals Genes Affected by FAK Inhibitor Y15 and Combination of Y15 and Temozolomide
Anti-Cancer Agents in Medicinal Chemistry New Developments and Prospective Applications for β (1,3) Glucans
Recent Patents on Biotechnology Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Electron Emission of Phytohormone Genistein. Pathway for Communication
Current Bioactive Compounds Optimizing Anti-EGFR Strategies in Cancer Treatment
Current Cancer Therapy Reviews Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Current Pharmaceutical Design Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Gold and Silver Nanoparticles in Bioassay, Cell Visualization and Therapy
Current Clinical Pharmacology <i>Fagonia indica</i>; A Review on Chemical Constituents, Traditional Uses and Pharmacological Activities
Current Pharmaceutical Design